362 related articles for article (PubMed ID: 24468755)
1. Breast cancer and osteoporosis.
Cheung AM; Heisey R; Srighanthan J
Curr Opin Endocrinol Diabetes Obes; 2013 Dec; 20(6):532-8. PubMed ID: 24468755
[TBL] [Abstract][Full Text] [Related]
2. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitors and bone health.
Bundred NJ
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
[TBL] [Abstract][Full Text] [Related]
4. Prevention of osteoporosis after breast cancer.
Reid DM
Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
6. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis and treatment of osteoporosis in nonmetastatic breast cancer].
Eiken PA; Hansen M; Kristensen B; Langdahl BL; Abrahamsen B
Ugeskr Laeger; 2011 Feb; 173(8):577-81. PubMed ID: 21333258
[TBL] [Abstract][Full Text] [Related]
9. Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Tang SC
Oncology; 2010; 79(1-2):13-26. PubMed ID: 21051913
[TBL] [Abstract][Full Text] [Related]
10. [Expert group consensus: prevention, diagnosis and treatment of bone loss and osteoporosis in postmenopausal breast cancer patients after aromatase inhibitor therapy].
Xiu Bing-He ;
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):876-9. PubMed ID: 24447490
[No Abstract] [Full Text] [Related]
11. Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.
Rozenberg S; Carly B; Liebens F; Antoine C
Maturitas; 2009 Sep; 64(1):1-3. PubMed ID: 19709824
[TBL] [Abstract][Full Text] [Related]
12. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
[TBL] [Abstract][Full Text] [Related]
13. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
[TBL] [Abstract][Full Text] [Related]
14. The role of bisphosphonates in the adjuvant setting for breast cancer.
Reeder JG; Brufsky AM
Oncology (Williston Park); 2010 May; 24(6):462-7, 475. PubMed ID: 20568587
[TBL] [Abstract][Full Text] [Related]
15. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Hadji P; Bundred N
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
[TBL] [Abstract][Full Text] [Related]
16. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
18. Emerging bone health issues in women with breast cancer in Hawai'i.
Carney JF; Davis J
Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
[TBL] [Abstract][Full Text] [Related]
19. Bone-Targeted Therapy in Early Breast Cancer.
Jerzak KJ; Raphael J; Desautels DN; Blanchette PS; Tyono I; Pritchard KI
Oncology (Williston Park); 2018 Nov; 32(11):562-9. PubMed ID: 30474104
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
